PNC1 (ECOG-ACRIN EA8134)

 
 
InPACT: International Penile Advanced Cancer Trial
Status: Planned
NCT Registration ID (from clinicaltrials.gov): NCT02305654
EudraCT: 2015-001199-23

Summary

    InPACT: International Penile Advanced Cancer Trial
    Complexity Level: 2

    Eligibility: (1) Male, aged 18 years or older, (2) Histologically-proven squamous cell carcinoma of the penis. (3) Stage: any T, N1 (i.e. a palpable mobile unilateral inguinal lymph node), M0, OR; any T, N2 (i.e. palpable mobile multiple or bilateral inguinal lymph nodes), M0 OR; any T, N3 (i.e. fixed inguinal nodal mass or any pelvic lymphadenopathy), M0, (4) Measurable disease as determined by RECIST (version 1.1) criteria, (5)Performance Status ECOG 0, 1 or 2, (6) Patient is fit to receive the randomisation options for which he is being considered. (7) adequate hematology, biochemistry, liver function, renal function tests, and patient must be suitable for randomization options. EXCLUSION: Pure verrucous carcinoma of the penis; Non-squamous malignancy of the penis; Squamous carcinoma of the urethra; Stage M1; Previous chemotherapy or chemoradiotherapy outside of the InPACT trial.

    Objectives: Primary objective: (1) (a) Is there a role for neoadjuvant therapy and, if so, (b) does CT or CRT produce superior outcomes (2) What is the additional survival benefit of PLND given after neoadjuvant s or with adjuvant CRT of the pelvic nodes over and above that of chemoradiotherapy alone in patients at high risk of recurrence following ILND? Secondary objectives: In InPACT-neoadjuvant: (a) Can neoadjuvant therapy prior to surgery (ILND) reduce recurrence rates? (b) Which is the more active of neoadjuvant CT or neoadjuvant CRT? (c) What is the op/post-op complication rate following neoadjuvant therapy of both types? (c) Is neoadjuvant CRT feasible in this setting? In InPACT-pelvis: (a) What is the rate of additional complications for the combination of PLND and CRT? Exploratory objectives: (a) What is the relationship between HPV status and outcome for all groups studied? (b) What is the impact on QOL of (sequential) treatments studied?

    NCT Registration ID (from clinicaltrials.gov): NCT02305654
    Participation: Open to member centres
    NCI US Affiliation: Yes
    Clinical Trials Application (Canada): Yes
    Coordination: Intergroup Led Trial
    Status: Planned

    Enrollments:

    Chair: (Canada) Dr. Juanita Crook, BCCA - Cancer Centre for the Southern Interior, (250) 712-3900 Ext. 3979



DSMC Reports

  • NA

Spring Meeting Report

Publications

  • Pending - Primary Publication
Lead Group Protocol Coordinator: James Corkery
Study Coordinator: Paul Stos 613-533-6430
Clinical Trials Assistant: Amy Hawkins 613-533-6430
Ethics Research Associate: Centre Contact 613-533-6430

Consent

  • English:
    Main Neo-Adjuvant - 2018MAR15: Word
    Main Pelvis - 2018MAR15: Word
    Optional - 2018MAR15: Word
    Exposure - 2018MAR15: Word
    Pregnancy - 2018MAR15: Word
  • French:
    Main Neo-Adjuvant - 2018MAR15: Word
    Main Pelvis - 2018MAR15: Word
    Optional - 2018MAR15: Word
    Exposure - 2018MAR15: Word
    Pregnancy - 2018MAR15: Word

Memos

  • NA

News / Miscellaneous

  • NA
  • Per Case Funding
  • Request for Additional Funding Pending